CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...